The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
NMDA Receptor and Schizophrenia: A Brief History
Open accessAbstract
Although glutamate was first hypothesized to be involved in the pathophysiology of schizophrenia in the 1980s, it was the demonstration that N-methyl-D-aspartate (NMDA) receptor antagonists, the dissociative anesthetics, could replicate the full range of psychotic, negative, cognitive, and physiologic features of schizophrenia in normal subjects that placed the "NMDA receptor hypofunction hypothesis" on firm footing. Additional support came from the demonstration that a variety of agents that enhanced NMDA receptor function at the glycine modulatory site significantly reduced negative symptoms and variably improved cognition in patients with schizophrenia receiving antipsychotic drugs. Finally, persistent blockade of NMDA receptors recreates in experimental animals the critical pathologic features of schizophrenia including downregulation of parvalbumin-positive cortical GABAergic neurons, pyramidal neuron dendritic dysgenesis, and reduced spine density.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Structure of Scientific Revolutions
Kuhn, T. S., & Schlegel, R. (1963) · Physics Today · doi:10.1063/1.3050879 · Cited by 35,538
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
The Logic of Scientific Discovery
(2013) · A Realist Theory of Science · doi:10.4324/9780203090732-9 · Cited by 7,731
Bliss, T. V. P., & Gardner‐Medwin, A. R. (1973) · The Journal of Physiology · doi:10.1113/jphysiol.1973.sp010274 · Cited by 7,437
Federation Proceedings: Water and Electrolyte Losses in Cholera
Phillips, R. A. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1982.tb05283.x · Cited by 3,934
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus Oocytes
Kleckner, N. W., & Dingledine, R. (1988) · Science · doi:10.1126/science.2841759 · Cited by 1,422
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
Sensorimotor Gating and Schizophrenia: Human and Animal Model Studies
Braff, D. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810140081011 · Cited by 1,309
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Self-citationReversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., Sampson, A. R., & Lewis, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06315.2003 · Cited by 938
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Self-citationSelemon, L. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220015005 · Cited by 876
Kirov, G., Pocklington, A. J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., Moran, J., Chambert, K., Toncheva, D., Georgieva, L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.154 · Cited by 844
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., & Holzmüller, B. (1980) · Neuroscience Letters · doi:10.1016/0304-3940(80)90178-0 · Cited by 694
Development and plasticity of cortical processing architectures
Singer, W. (1995) · Science · doi:10.1126/science.270.5237.758 · Cited by 669
Schizophrenia as a Disorder of Developmentally Reduced Synaptic Connectivity
McGlashan, T. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.7.637 · Cited by 655
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Self-citationPhencyclidine-induced psychosis
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.9.1081 · Cited by 478
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindström, L. H., & Engberg, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02242-x · Cited by 471
NMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Self-citationVentricular enlargement in schizophrenia: relationship to positive and negative symptoms
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.3.297 · Cited by 426
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
BEASLEY, C., & REYNOLDS, G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00122-3 · Cited by 426
Modulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 411
Self-citationBeneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
Knable, M. B., Barci, B. M., Webster, M. J., Meador-Woodruff, J., & Torrey, E. F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001471 · Cited by 407
Specific [3H]phencyclidine binding in rat central nervous system.
Zukin, S. R., & Zukin, R. S. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.10.5372 · Cited by 380
Kegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J. J., Van Heertum, R. L., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 377
Amelioration of negative symptoms in schizophrenia by glycine
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 354
Dendrodendritic Inhibition in the Olfactory Bulb Is Driven by NMDA Receptors
Schoppa, N. E., Kinzie, J. M., Sahara, Y., Segerson, T. P., & Westbrook, G. L. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-17-06790.1998 · Cited by 333
Tsai, G., & Lin, P.-Y. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269
MODEL PSYCHOSES AND SCHIZOPHRENIA
LUBY, E. D., GOTTLIEB, J. S., COHEN, B. D., ROSENBAUM, G., & DOMINO, E. F. (1962) · American Journal of Psychiatry · doi:10.1176/ajp.119.1.61 · Cited by 268
A “Glutamatergic Hypothesis” of Schizophrenia: Rationale for Pharmacotherapy with Glycine
Deutsch, S. I., Mastropaolo, J., Schwartz, B. L., Rosse, R. B., & Morihisa, J. M. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198902000-00001 · Cited by 268
Bird, E., Barnes, J., Iversen, L., Spokes, E., Mackay, A. P., & Shepherd, M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91542-2 · Cited by 256
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255
(3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
Kornhuber, J., Mack-Burkhardt, F., Riederer, P., Hebenstreit, G. F., Reynolds, G. P., Andrews, H. B., & Beckmann, H. (1989) · Journal of Neural Transmission · doi:10.1007/bf01248936 · Cited by 250
NMDA receptors and schizophrenia
KRISTIANSEN, L., HUERTA, I., BENEYTO, M., & MEADORWOODRUFF, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.013 · Cited by 246
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243
Kerwin, R., Patel, S., & Meldrum, B. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90219-t · Cited by 239
Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
Harrison, P. J., McLaughlin, D., & Kerwin, R. W. (1991) · The Lancet · doi:10.1016/0140-6736(91)93392-m · Cited by 238
Farber, N. B., Wozniak, D. F., Price, M. T., Labruyere, J., Huss, J., St. Peter, H., & Olney, J. W. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00046-1 · Cited by 219
D-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Carlsson, M., & Carlsson, A. (1989) · Journal of Neural Transmission · doi:10.1007/bf01255820 · Cited by 174
Selemon, L. D., Mrzljak, J., Kleinman, J. E., Herman, M. M., & Goldman, P. S. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.69 · Cited by 158
Schizophrenia as a developmental disorder of the cerebral cortex
Raedler, T. J., Knable, M. B., & Weinberger, D. R. (1998) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(98)80019-6 · Cited by 155
Glutamatergic Regulation of Basal and Stimulus‐Activated Dopamine Release in the Prefrontal Cortex
Takahata, R., & Moghaddam, B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71041443.x · Cited by 142
Li, Q., Clark, S., Lewis, D. V., & Wilson, W. A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03070.2002 · Cited by 142
Bliss, T. V. P., & Lømo, T. (1973) · The Journal of Physiology · doi:10.1113/jphysiol.1973.sp010273 · Cited by 135
GOFF, D. C., Herz, L. R., Posever, T. A., Shih, V. E., Tsai, G. E., Henderson, D. C., Freudenreich, O., Evins, A. E., Yovel, I., Zhang, H., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2032-2 · Cited by 116
Low dose ketamine increases prepulse inhibition in healthy men
Abel, K. M., Allin, M. P. G., Hemsley, D. R., & Geyer, M. A. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00073-x · Cited by 114
Perry, T. L. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90212-9 · Cited by 112
Free and conjugated amino acids in human CSF: Influence of age and sex
Ferraro, T. N., & Hare, T. A. (1985) · Brain Research · doi:10.1016/0006-8993(85)90247-1 · Cited by 112
Zhang, Y., Behrens, M. M., & Lisman, J. E. (2008) · Journal of Neurophysiology · doi:10.1152/jn.00079.2008 · Cited by 107
Balu, D. T., Basu, A. C., Corradi, J., Cacace, A. M., & Coyle, J. T. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.006 · Cited by 103
Self-citationOlanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity
Farber, N. B., Foster, J., Duhan, N. L., & Olney, J. W. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(96)00024-2 · Cited by 101
Glycine Adjuvant Therapy to Conventional Neuroleptic Treatment in Schizophrenia
Rosse, R. B., Theut, S. K., Banay‐Schwartz, M., Leighton, M. P., Scarcella, E., Cohen, C. G., & Deutsch, S. I. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198910000-00006 · Cited by 101
Glutamate: a new target in schizophrenia?
Wachtel, H., & Turski, L. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90243-2 · Cited by 99
Schuster, G., & Schmidt, W. J. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)94825-g · Cited by 95
Leiderman, E. A., Zylberman, I., Zukin, S. R., Cooper, T. B., & Javitt, D. C. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00585-4 · Cited by 92
MULTIPLE SCLEROSIS AND MACROCYTOSIS
Crellin, R. F., Bottiglieri, T., & Reynolds, E. H. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91521-3 · Cited by 90
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Coyle, J. T., Balu, D. T., Benneyworth, M. A., Basu, A. C., & Roseman, A. S. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jcoyle · Cited by 84
Self-citationReduced striatal spine size in schizophrenia
Roberts, R. C., Conley, R. R., Kung, L., Peretti, F. J., & Chute, D. J. (1996) · Neuroreport · doi:10.1097/00001756-199604260-00024 · Cited by 84
Ramsey, A. J., Milenkovic, M., Oliveira, A. F., Escobedo-Lozoya, Y., Seshadri, S., Salahpour, A., Sawa, A., Yasuda, R., & Caron, M. G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012621108 · Cited by 81
Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia
Tsai, G. E., van Kammen, D. P., Chen, S., Kelley, M. E., Grier, A., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00151-6 · Cited by 80
Self-citationDo, K. Q., Lauer, C. J., Schreiber, W., Zollinger, M., Gutteck‐Amsler, U., Cuénod, M., & Holsboer, F. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65062652.x · Cited by 79
Genetics in schizophrenia: where are we and what next?
Tiwari, A. K., Zai, C. C. H., Müller, D. J., & Kennedy, J. L. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/atiwari · Cited by 75
Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics
Sherman, A. D., Hegwood, T. S., Baruah, S., & Waziri, R. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90155-f · Cited by 70
Paradigms of psychiatry: eclecticism and its discontents
Ghaemi, S. N. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000245751.98749.52 · Cited by 57
Möhler, H., Boison, D., Singer, P., Feldon, J., Pauly-Evers, M., & Yee, B. K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.003 · Cited by 53
Tamminga, C. A., Tanimoto, K., Kuo, S., Chase, T. N., Contreras, P. C., Rice, K. C., Jackson, A. E., & O’Donohue, T. L. (1987) · Synapse · doi:10.1002/syn.890010514 · Cited by 50
Spokes, E. G., Garrett, N., & Iversen, L. L. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05223.x · Cited by 49
Yurgelun-Todd, D. A., Coyle, J. T., Gruber, S. A., Renshaw, P. F., Silveri, M. M., AMICO, E. T., Cohen, B. M., & GOFF, D. C. (2005) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.11.006 · Cited by 47
Self-citationSwerdlow, N. R. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_48 · Cited by 43
Kim, J. S., Kornhuber, H. H., Brand, U., & Menge, H. G. (1981) · Neuroscience Letters · doi:10.1016/0304-3940(81)90365-7 · Cited by 41
Vulnerability to psychosis associated with hallucinogen use
Bowers, M. B., & Swigar, M. E. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90030-6 · Cited by 36
Boteva, K., & Lieberman, J. A. (2003) · The World Journal of Biological Psychiatry · doi:10.3109/15622970309167956 · Cited by 32
Liem-Moolenaar, M., Zoethout, R., de Boer, P., Schmidt, M., de Kam, M., Cohen, A., Franson, K. L., & van Gerven, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109105573 · Cited by 27
Etienne, P. E., & Baudry, M. (1990) · Springer eBooks · doi:10.1007/978-3-7091-9050-0_5 · Cited by 12
Weinstein, H., Maayani, S., & Pazhenchevsky, B. (1983) · PubMed · Cited by 6
Cited by
Hippocampal GABAergic Inhibitory Interneurons
Pelkey, K. A., Chittajallu, R., Craig, M. T., Tricoire, L., Wester, J. C., & McBain, C. J. (2017) · Physiological Reviews · doi:10.1152/physrev.00007.2017 · Cited by 889
From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways
Rogers, G. B., Keating, D. J., Young, R. L., Wong, M.-L., Licinio, J., & Wesselingh, S. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.50 · Cited by 969
Correll, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
Genetic insights into the neurodevelopmental origins of schizophrenia
Birnbaum, R., & Weinberger, D. R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.125 · Cited by 494
Kynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
Metadata
- Authors
- Coyle, J. T.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-01
- Volume
- 38
- Issue
- 5
- Pages
- 920-926
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2112445212
- Cited by
- 410
- References
- 92
- FWCI
- 17.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.